Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower- Middle Income Country? A Cost-Utility Analysis in the Philippines

Manuel Alexander Haasis, Joyce Anne Ceria, Wantanee Kulpeng, Yot Teerawattananon, Marissa Alejandria

Jul. 6, 2015

The objective of this study is to assess the value for money of introducing pneumococcal conjugate vaccines as part of the immunization program in a lower-middle income country, the Philippines, which is not eligible for GAVI support and lower vaccine prices. It also includes the newest clinical evidence evaluating the efficacy of PCV10, which is lacking in other previous studies.

Citation: Haasis MA, Ceria JA, Kulpeng W, Teerawattananon Y, Alejandria M (2015) Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines. PLoS ONE 10(7): e0131156. doi:10.1371/journal.pone.0131156

Nov. 26, 2015 Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines "The objective of this study is to assess the value for money of introducing pneumococcal conjugate vaccines as part of the immunization program in a lower-middle income country, the Philippines,… READ MORE

Feb. 1, 2013 Incorporating Financial Protection into Decision Rules for Publicly Financed Healthcare Treatments Almost all health systems seek to offer some form of publicly financed healthcare insurance, and governments must therefore choose the size of the benefit package and the types of treatments… READ MORE

Apr. 28, 2015 Policy Note: Process Matters for Priority Setting and Health Technology Assessment This discussion outlines some key principles and activities which can be used to support open, consultative and independent processes for health technology assessment in Indonesia. READ MORE